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abstract
Keywords:

Methamphetamine is a highly addictive psychostimulant with tens of millions of abusers

Adeno-associated virus

around the world. There is no effective or approved medication for treating an addiction to

Antibody

it. Monoclonal antibodies with a high affinity for methamphetamine have the potential to

Methamphetamine

sequester the drug in the vascular compartment and reduce entry into the brain, thereby
acting as peripheral pharmacokinetic antagonists without inducing adverse effects on
neurons. However, to maintain the antibodies at an effective level, repeated administration
is required, which would be expensive and problematic for patient compliance. In this
study, we intended to investigate whether using a recombinant adeno-associated virusmediated gene transfer technique can be an effective approach to achieve long-term
expression of anti-methamphetamine monoclonal antibodies in mouse models. We
generated a recombinant adeno-associated virus vector encoding the heavy and light
chains of an anti-methamphetamine monoclonal antibody, which was constructed in a
single open reading frame and linked with a 2A self-processing sequence. In the context of
virus-mediated gene transfer, the expression of full-length and functional monoclonal
antibodies was successfully demonstrated in vitro and in vivo. Further investigations are
ongoing concerning dose optimization, longterm expression, and protection from methamphetamine challenge in mouse models.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Methamphetamine (Meth) is an illicit, highly addictive stimulant of the central nervous system (CNS); it is estimated that

there are more than 35 million Meth abusers in the world [1].
During the past two decades, governments throughout the
world have attempted to conquer Meth abuse; however, it
continues to be a major public health problem that needs to be
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tackled on a global scale. Meth abuse can cause numerous
adverse biological effects on many organ systems such as acute
toxic effects on the cardiovascular system and CNS, acute renal
failure, altered behavioral and cognitive functions, and persistent neurological damage to the brain [2,3]. A growing body of
evidence has also indicated that Meth can suppress innate and
adoptive immunity, and increase susceptibility to viral pathogens such as human immunodeficiency virus [4,5]. There is no
approved medication for Meth abuse, and the broad mechanism
of Meth action makes it difficult to develop an effective small
molecule for pharmacotherapeutic intervention [6,7].

Fig. 1 e The concept of antibody-based therapy for
methamphetamine abuse. Methamphetamine enters the
bloodstream, but it can move across the bloodebrain
barrier (BBB) and freely access its activation sites in the
brain, thereby causing adverse psychological and craving
effects (left). In the presence of an anti-methamphetamine
antibody in the bloodstream, methamphetamine
molecules are captured and confined in the circulation,
which reduces the entry of the drug into the central
nervous system (right). The red closed circles are
methamphetamine molecules; the green Y-shaped figures
are anti-methamphetamine antibodies.

2.
The principle of anti-methamphetamine
immunotherapy
Antibodies with a high affinity for Meth can sequester the
drug molecules in the bloodstream and prevent their gaining
access to their activation sites in the CNS or other vulnerable
organs (Fig. 1), thereby acting as peripheral pharmacokinetic
antagonists that terminate the drug-induced reinforcing effects [8,9]. Because antibodies are too large to readily traverse
the bloodebrain barrier, an antibody-bound drug molecule
cannot freely enter the brain, thus resulting in a drug concentration gradient that allows a free drug molecule to leave
the brain at a relatively greater rate than it enters [8].

Fig. 2 e Approaches for generating anti-methamphetamine antibodies in the bloodstream for the treatment of
methamphetamine abuse. Antibody-based therapy for methamphetamine (Meth) abuse encompasses three potential
approaches: (1) individuals can receive drug-specific vaccines to generate their own anti-Meth polyclonal antibodies; (2)
antibodies with a high affinity for Meth can be isolated from antibody libraries there are expressed from various
microorganism systems or from antibody-producing hybridoma cells derived from vaccinated animals; these preselected
antibodies can be genetically modified to form human-compatible antibodies in suitable expression systems for passive
transfer into the peripheral circulation; and (3) expression of anti-Meth antibodies can be achieved by recombinant adenoassociated virus (rAAV)-mediated gene transfer into humans.
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3.
Approaches for generating antimethamphetamine antibodies
In general, drug-specific antibodies can be generated in a patient’s bloodstream by active and passive immunization approaches (Fig. 2). In active immunization, drug-like antigens
are repeatedly administrated via traditional vaccination procedures to generate a patient’s own polyclonal antibodies
against the target drugs [10]. The passive immunization
approach is performed by the intravenous administration of
well-characterized and genetically engineered monoclonal
antidrug antibodies, which are derived from vaccinated animals or antibody libraries [11,12]. In fact, these immunization
approaches have been investigated for the treatment of Meth
abuse in several rodent models and have shown promising
results [13,14].
Drug-specific immunization approaches could potentially
avoid inducing unwanted neuromodulatory effects in the
brain, although several limitations should be carefully
considered prior to treating drug abuse with this approach.
The drug molecule itself cannot reactivate the vaccineinduced antidrug immune response to regenerate antidrug
antibodies[15,16]; the preformed antibodies will be disabled by
forming long-lived complexes with the captured drugs and be
eliminated gradually after being infused into the circulation
[10,17].
Therefore, to maintain an effective level of antidrug antibodies, a well-scheduled and repeated administration course
is required for both immunization approaches, which would
be costly and become a major barrier to patient adherence. In
addition, although the drug vaccine is designed to induce
drug-specific antibodies, active immunization could potentially induce antibodies with unwanted reactivity to endogenous molecules or tissue antigens, which may then reduce the
therapeutic efficacy. Therefore, we proposed an alternative
approach for the longterm expression of Meth-specific antibodies in vivo via recombinant adeno-associated virus (rAAV)mediated gene transfer.

4.
Recombinant adeno-associated virusmediated expression of anti-methamphetamine
antibodies
The rAAV vector has been widely used in gene therapy applications, largely because of its low immunogenicity and
nonpathogenicity for humans and because of its capability to
transduce a broad range of cell types and achieve longterm
gene expression [18,19]. In this study, we generated a rAAV
serotype-8 (rAAV8) vector carrying an antibody expression
cassette (Fig. 3) in which the heavy chain and light chain sequences of a well-characterized anti-Meth monoclonal antibody (KD ¼ 11 nM) were separated by a furin-2A self-cleavage
site [13,20].
The anti-Meth antibodies expressed in HEK 293 cells
infected with the rAAV8 vector were purified from a culture
medium, and the antibodies have been shown to capture Meth
molecules in a colorimetric assay (Fig. 4). Thus, anti-Meth
antibodies expressed from the furin-2A construct are

produced in the secreted form and retain the binding activity
to Meth molecules. To evaluate rAAV8-mediated expression
of anti-Meth antibodies in vivo, adult mice were intraperitoneally injected with a rAAV8 vector (at a dose of 109 genome
copies/mouse). The serum levels of anti-Meth antibodies were
evaluated over time. The anti-Meth antibody was detected at
14 days post-administration of the rAAV8 vector, and a 12-fold
higher serum level (p < 0.001) was achieved at 47 days postadministration (Fig. 5A). Longterm evaluation is still ongoing.
We further investigated whether anti-Meth antibodies
generated by rAAV8-mediated gene transfer can attenuate
Meth-induced behavioral changes. Mice were intraperitoneally injected with Meth (1 mg/kg) at 50 days post-administration of the rAAV8 vector. For 90 minutes, the postchallenge
locomotor activity was recorded as the total distance traveled.
Compared to the locomotor activity of the mock-infected
group (n ¼ 4), the Meth-induced locomotor activity in the
group (n ¼ 3) receiving the rAAV8 vector was reduced by 30%
(p ¼ 0.084; Fig. 5B). The difference did not reach statistical
significance; however, these data demonstrated that a single
administration of a low dose of rAAV8 is able to achieve peripheral expression of functional anti-Meth antibodies to
attenuate Meth-induced behavioral changes in mice. However, this study only presented preliminary results, and the
animal numbers were not sufficient to satisfy statistical
criteria. The virus vector was also administrated at a low
dosage. In future work, there should be numerous chances

Fig. 3 e Schematic illustration of the genetic construction
and biosynthesis of the anti-methamphetamine
monoclonal antibody. The heavy-chain and light-chain
genes of a preselected anti-methamphetamine antibody
are constructed in a single open reading frame, which is
linked together by a sequence coding for a combination of
furin cleavage site (FCS) and 2A self-processing sequence
(derived from the foot-and-mouth disease virus), driven by
the cytomegalovirus (CMV) promoter. During protein
biosynthesis, the encoded 2A sequence can disrupt
peptide-bond formation at the C-terminus of 2A without
devastating the synthesis of the downstream protein. The
FCS allows enzymatic removal of 2A sequence from the Cterminus of the translated heavy chain. The coexpressed
heavy chain and light chain proteins finally self-assemble
to form a functional antibody in cells receiving the
expression cassette of the anti-methamphetamine
antibody. SP [ signal peptide.
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Fig. 4 e A colorimetric assay for quantitative determination of anti-methamphetamine antibodies. Antibodies can be
captured by protein-G-conjugated sepharose beads. After washing off the unbound methamphetamine (Meth) conjugated
with horseradish peroxidase (HRP), the conversion of the HRP substrates to blue-colored substances indicates the presence
of anti-Meth antibodies. If color changes do not occur, the captured antibody has no binding activity to Meth. The color
intensity is proportional to the amount of anti-Meth antibodies captured by the beads. Anti-V5 is a mouse monoclonal
antibody specific to a 14-amino acid V5 epitope derived from the simian parainfluenza virus type 5. The green Y-shaped
figures are the antibodies.

Fig. 5 e The expression of anti-methamphetamine monoclonal antibody in vivo by rAAV8-mediated gene transfer. Male ICR
strain mice (8 weeks old age) that were intraperitoneally injected with PBS (n [ 4) or rAAV8 (n [ 3) carry the expression
cassette of an anti-methamphetamine (Meth) antibody. (A) Serum samples were collected at indicated time points (0 days,
14 days postadministration, and 47 days postadministration) for measuring the expression levels of anti-Meth antibodies
by colorimetric assay. (B) The animals were challenged with Meth at a dose of 1 mg/kg through intraperitoneal injection on
Day 50 postadministration of rAAV8, and the induced locomotor activity was recorded as the total distance traveled (in
centimeters) in 90 minutes. All animal studies were conducted under protocols reviewed and approved by the National
Health Research Institutional Animal Care and Use Committee. The horizontal lines are the mean distance traveled.
Statistical differences are determined by using a two-sample t-test.
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and many ways to improve protection from a Meth-challenge
following rAAV8-mediated gene transfer.
[5]

5.

Conclusions
[6]

We are conducting further investigations focusing on
increasing virus dosages to achieve higher serum levels of
anti-Meth antibodies in a sample size with sufficient statistical power. Furthermore, an antibody highly specific to
amphetamine (a pharmacologically active metabolite of Meth)
is also applied in the rAAV8-mediated gene transfer approach.
The safety and efficacy of rAAV-mediated expression of antiMeth antibodies in humans remains to be addressed. However, we envision that this gene transfer approach, when used
in combination with appropriate counseling, would greatly
increase the likelihood of successful treatment of Meth
dependence. Furthermore, this gene transfer approach could
potentially be applied to treatment for other drugs of abuse.
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